LON:AVOAdvanced Oncotherapy Share Price, Forecast & News

Advanced Oncotherapy's stock was trading at GBX 32.50 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, AVO stock has decreased by 22.5% and is now trading at GBX 25.20.
View which stocks have been most impacted by Coronavirus.

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Advanced Oncotherapy in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Advanced Oncotherapy.

Advanced Oncotherapy PLC (LON:AVO) posted its quarterly earnings results on Monday, June, 29th. The company reported ($9.83) EPS for the quarter, missing analysts' consensus estimates of ($8.90) by $0.93.
View Advanced Oncotherapy's earnings history.

1 Wall Street analysts have issued 12-month target prices for Advanced Oncotherapy's shares. Their forecasts range from GBX 155 to GBX 155. On average, they anticipate Advanced Oncotherapy's share price to reach GBX 155 in the next year. This suggests a possible upside of 515.1% from the stock's current price.
View analysts' price targets for Advanced Oncotherapy.

Press coverage about AVO stock has trended somewhat negative on Tuesday, InfoTrie Sentiment reports. The research firm ranks the sentiment of press coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Advanced Oncotherapy earned a media sentiment score of -1.7 on InfoTrie's scale. They also assigned news articles about the company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an impact on the company's share price in the next few days.
View the latest news about Advanced Oncotherapy.

Some companies that are related to Advanced Oncotherapy include Creo Medical Group (CREO), Hamilton Thorne (HTL), Imricor Med SYS Cdi 1:1 US Person Prohibited Excluding QIB (IMR), Medica Group (MGP), Electromed (ELMD), Electromed (ELMD), Cyclopharm (CYC), Patient Home Monitoring (PTQ), Titan Medical (TMD), Somnomed (SOM), Resonance Health (RHT), REVA Medical (RVA), MRI Interventions (CLPT), Total Brain (TTB) and EMvision Medical Devices (EMV).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Advanced Oncotherapy investors own include UK Oil & Gas (UKOG), Avesoro Resources (ASO), BMR Group (BMR), GW Pharmaceuticals PLC- (GWPH), Lancashire (LRE), Oxford BioMedica (OXB), Sirius Minerals (SXX), Renishaw (RSW), Scancell (SCLP) and Tullow Oil (TLW).

Advanced Oncotherapy trades on the London Stock Exchange (LON) under the ticker symbol "AVO."

Shares of AVO and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

One share of AVO stock can currently be purchased for approximately GBX 25.20.

Advanced Oncotherapy has a market capitalization of £77.21 million. Advanced Oncotherapy employs 93 workers across the globe.

The official website for Advanced Oncotherapy is www.advancedoncotherapy.com.

Advanced Oncotherapy's mailing address is Third Fl Clearwater HSE, 4-7 Manchester Street, LONDON, W1U 3AE, United Kingdom. The company can be reached via phone at +44-20-36178728.